BioThrust completed a pre-seed extension financing round to advance its cell and gene therapy technology. The funding amount was not disclosed. The capital will be used mainly for international pilot studies to prove industrial scalability and build data for commercialization. Existing investors include RWTH Aachen University and Freigeist. New investors include ALAGO, NRW.BANK, and Theo Bongartz. The company is also supported by several business angels from science and industry.
About BioThrust
Biotech startup developing the "ComfyCell" bioreactor platform to make stem cell manufacturing more efficient and scalable for cell and gene therapies.
Aachen, Germany
Read Company ProfileFrequently Asked Questions
What type of funding round did BioThrust raise?
BioThrust raised a pre-seed round.
When did BioThrust raise its pre-seed?
BioThrust raised its pre-seed on 2026-04-28.
Who invested in BioThrust's pre-seed?
The investors in BioThrust's pre-seed are: RWTH Aachen University, Freigeist, ALAGO, NRW.BANK, Theo Bongartz.
What type of investment was BioThrust's pre-seed?
BioThrust's pre-seed was a equity investment.
How will BioThrust use the funds from its pre-seed?
BioThrust plans to use the funds for: international pilot studies, demonstrate industrial scalability of the technology, build a robust data basis for commercialization.